Unum Therapeutics (UMRX) IPO Opens Modestly Lower

Today's IPO for Unum Therapeutics Inc. (NASDAQ: UMRX) opened for trading at $11.75 pricing of its initial public offering of 5,770,000 shares of common stock at a public offering price of $12 per share.

In addition, Unum Therapeutics has granted the underwriters a 30-day option to purchase up to 865,500 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Morgan Stanley and Cowen are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey and Wedbush PacGrow are acting as lead managers.

Unum Therapeutics uses its proprietary antibody-coupled T cell receptor (ACTR) technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum Therapeutics is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor cancers. The Company is headquartered in Cambridge, MA.

You May Also Be Interested In